{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:39Z","timestamp":1790916819434,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"\n Aim<\/jats:title>\n \n This study aimed to evaluate the impact of\n CYP3A5<\/jats:italic>\n gene polymorphism on the pharmacokinetics, therapeutic efficacy, and safety of tacrolimus in pediatric patients with Henoch\n \u2013<\/jats:bold>\n Sch\u00f6nlein purpura nephritis (HSPN).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This study used a retrospective observational design to investigate pediatric patients with HSPN treated with tacrolimus. The polymorphism at the\n CYP3A5<\/jats:italic>\n was detected using PCR technology. The concentration of tacrolimus was quantitatively determined by ultra-performance liquid chromatography. The study systematically analyzed the impact of\n CYP3A5<\/jats:italic>\n gene polymorphism on the pharmacokinetic parameters of tacrolimus (including trough concentration\n C<\/jats:italic>\n 0<\/jats:sub>\n , dose\n D<\/jats:italic>\n , and dose-corrected concentration\n C<\/jats:italic>\n 0<\/jats:sub>\n \/\n D<\/jats:italic>\n ), clinical efficacy, and adverse reactions.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The study enrolled 103 pediatric patients. Comparative analysis revealed that patients with\n CYP3A5*1\/*1<\/jats:italic>\n or\n *1\/*3<\/jats:italic>\n genotypes exhibited significantly lower tacrolimus\n C<\/jats:italic>\n 0<\/jats:sub>\n and\n C<\/jats:italic>\n 0<\/jats:sub>\n \/\n D<\/jats:italic>\n at various time points when compared with\n CYP3A5*3\/*3 g<\/jats:italic>\n enotype carriers. Furthermore,\n CYP3A5*1<\/jats:italic>\n expressers (\n CYP3A5*1\/*1<\/jats:italic>\n and\n *1\/*3<\/jats:italic>\n ) demonstrated markedly reduced tacrolimus\n C<\/jats:italic>\n 0<\/jats:sub>\n and\n C<\/jats:italic>\n 0<\/jats:sub>\n \/\n D<\/jats:italic>\n levels across multiple time points relative to\n CYP3A5*3<\/jats:italic>\n nonexpressers (\n CYP3A5*3\/*3<\/jats:italic>\n ). However,\n CYP3A5<\/jats:italic>\n genetic polymorphisms did not demonstrate significant associations with clinical efficacy or adverse reactions.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The polymorphism of the\n CYP3A5<\/jats:italic>\n gene may provide information on the pharmacokinetics of tacrolimus in pediatric with HSPN, but its clinical relevance has not yet been demonstrated.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000604","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:00:07Z","timestamp":1779393607000},"page":"245-257","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch\u2013Sch\u00f6nlein purpura nephritis"],"prefix":"10.1097","volume":"36","author":[{"given":"Huiying","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy,Yunnan Provincial Hospital of Infectious Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Kunming First People\u2019s Hospital, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fashuang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kunming Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"R1-20261002","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.12998\/wjcc.v11.i26.6311","article-title":"Delayed diagnosis of abdominal Henoch-Schonlein purpura in children: a case report.","volume":"11","author":"Guo","year":"2023","journal-title":"World J Clin Cases"},{"key":"R2-20261002","first-page":"271","article-title":"Clinical application of compound Glycyrrhizin tablets in the treatment of patients with simplex Henoch-Schonlein purpura and its effect on immune function.","volume":"38","author":"Li","year":"2022","journal-title":"Pak J Med Sci"},{"key":"R3-20261002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/jorc.12451","article-title":"A disease-targeted picture book for children with Henoch-Schonlein purpura nephritis: a quasi-experimental study.","volume":"49","author":"Tang","year":"2023","journal-title":"J Ren Care"},{"key":"R4-20261002","first-page":"259","article-title":"Changes of peripheral blood lymphocyte subsets and immune function in children with Henoch-Schonlein purpura nephritis.","volume":"18","author":"Su","year":"2021","journal-title":"Iran J Immunol"},{"key":"R5-20261002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12519-014-0534-5","article-title":"Henoch-Sch\u00f6nlein purpura nephritis in children: incidence, pathogenesis and management.","volume":"11","author":"Chen","year":"2015","journal-title":"World J Pediatr"},{"key":"R6-20261002","first-page":"1113","article-title":"[Therapeutic effect of mycophenolate mofetil or cyclophosphamide in children with Henoch-Sch\u00f6nlein purpura nephritis of different age groups].","volume":"25","author":"Du","year":"2023","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"R7-20261002","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cpt.3448","article-title":"Optimal trough concentration of tacrolimus in pediatric patients with primary nephrotic syndrome.","volume":"117","author":"Wang","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20261002","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00393-021-01087-z","article-title":"A network meta-analysis of randomized controlled trials comparing the effectiveness and safety of voclosporin or tacrolimus plus mycophenolate mofetil as induction treatment for lupus nephritis.","volume":"82","author":"Lee","year":"2023","journal-title":"Z Rheumatol"},{"key":"R9-20261002","doi-asserted-by":"crossref","first-page":"sfae115","DOI":"10.1093\/ckj\/sfae115","article-title":"The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases.","volume":"17","author":"Gan","year":"2024","journal-title":"Clin Kidney J"},{"key":"R10-20261002","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40272-022-00506-1","article-title":"Efficacy and safety of tacrolimus in the treatment of pediatric Henoch\u2013Sch\u00f6nlein purpura nephritis.","volume":"24","author":"Wu","year":"2022","journal-title":"Pediatr Drugs"},{"key":"R11-20261002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bcp.14174","article-title":"Off-label use of tacrolimus in children with glomerular disease: effectiveness, safety and pharmacokinetics.","volume":"86","author":"Hao","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R12-20261002","first-page":"53","article-title":"Pharmacogenomic analysis of CYP3A5*3 and tacrolimus trough concentrations in Vietnamese renal transplant outcomes.","volume":"17","author":"Nguyen","year":"2024","journal-title":"Pharmgenomics Pers Med"},{"key":"R13-20261002","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update.","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch Toxicol"},{"key":"R14-20261002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing.","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R16-20261002","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/gtmb.2017.0088","article-title":"Long-term influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 polymorphisms on tacrolimus concentration in Chinese renal transplant recipients.","volume":"21","author":"Liu","year":"2017","journal-title":"Genet Test Mol Biomarkers"},{"key":"R17-20261002","doi-asserted-by":"crossref","first-page":"688","DOI":"10.56434\/j.arch.esp.urol.20247706.94","article-title":"Association between CYP3A5 gene polymorphism and post-transplant acute immune rejection in renal transplant recipients receiving tacrolimus therapy: a correlation study.","volume":"77","author":"Jia","year":"2024","journal-title":"Arch Esp Urol"},{"key":"R18-20261002","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/10600280231197399","article-title":"CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and voriconazole in Chinese kidney transplant patients.","volume":"58","author":"Zhang","year":"2024","journal-title":"Ann Pharmacother"},{"key":"R19-20261002","doi-asserted-by":"crossref","first-page":"20420986241243165","DOI":"10.1177\/20420986241243165","article-title":"Drug-drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different CYP3A5 genotypes.","volume":"15","author":"Zhang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"R20-20261002","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/archdischild-2017-313788","article-title":"Off-label use of tacrolimus in children with Henoch-Sch\u00f6nlein purpura nephritis: a pilot study.","volume":"103","author":"Zhang","year":"2018","journal-title":"Arch Dis Child"},{"key":"R21-20261002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.transproceed.2011.11.004","article-title":"Impact of cytochromeP450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.","volume":"44","author":"Cho","year":"2012","journal-title":"Transplant P"},{"key":"R22-20261002","first-page":"647","article-title":"Diagnosis and treatment of purpura nephritis syndrome guidelines (2016).","volume":"55","year":"2017","journal-title":"Chin J Pediatr"},{"key":"R23-20261002","first-page":"911","article-title":"Evidence-based guidelines for the diagnosis and treatment of common pediatric kidney diseases (part II): evidence-based guidelines for the diagnosis and treatment of Henoch-Sch\u00f6nlein purpura nephritis (trial implementation).","volume":"47","year":"2009","journal-title":"Chin J Pediatr"},{"key":"R24-20261002","doi-asserted-by":"crossref","first-page":"1759720X211059610","DOI":"10.1177\/1759720X211059610","article-title":"Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis.","volume":"13","author":"Abu-Zaid","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R25-20261002","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-024-06502-6","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.","volume":"40","author":"Vivarelli","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"R26-20261002","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/pharmaceutics12090898","article-title":"Frequency of CYP3A5 genetic polymorphisms and tacrolimus pharmacokinetics in pediatric liver transplantation.","volume":"12","author":"Buend\u00eda","year":"2020","journal-title":"Pharmaceutics"},{"key":"R27-20261002","first-page":"853","article-title":"Polymorphism of CYP3A5*3 gene and its clinical significance in the Pearl River Delta population.","volume":"31","author":"Chen","year":"2021","journal-title":"Pharm Today"},{"key":"R28-20261002","doi-asserted-by":"crossref","first-page":"e14893","DOI":"10.1111\/ctr.14893","article-title":"Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.","volume":"37","author":"Reininger","year":"2023","journal-title":"Clin Transplant"},{"key":"R29-20261002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/PGPM.S339318","article-title":"Prediction of tacrolimus dose\/weight-adjusted trough concentration in pediatric refractory nephrotic syndrome: a machine learning approach.","volume":"15","author":"Mo","year":"2022","journal-title":"PGPM"},{"key":"R30-20261002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41397-019-0144-7","article-title":"CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.","volume":"20","author":"Khan","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R31-20261002","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00228-019-02726-w","article-title":"CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.","volume":"75","author":"Liu","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R32-20261002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40360-018-0202-9","article-title":"Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.","volume":"19","author":"Li","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"R33-20261002","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.intimp.2018.02.005","article-title":"Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.","volume":"57","author":"Liu","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"R34-20261002","first-page":"497","article-title":"Pharmacogenomics of tacrolimus in Asian renal transplant recipients: a systematic review and meta-analysis of the impact of CYP3A5 polymorphisms on dose requirements and clinical outcomes.","volume":"18","author":"Zhou","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R35-20261002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/pgs.13.199","article-title":"CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.","volume":"15","author":"Kurzawski","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R36-20261002","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.clinthera.2013.08.019","article-title":"Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.","volume":"35","author":"Vannaprasaht","year":"2013","journal-title":"Clin Ther"},{"key":"R37-20261002","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1111\/ajt.13788","article-title":"Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype.","volume":"16","author":"Pallen","year":"2016","journal-title":"Am J Transplant"},{"key":"R38-20261002","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation.","volume":"16","author":"Shuher","year":"2016","journal-title":"Am J Transplant"},{"key":"R39-20261002","first-page":"141","article-title":"Effects of CYP3A5 polymorphisms on efficacy and safety of tacrolimus therapy in patients with idiopathic membranous nephropathy.","volume":"13","author":"Zhang","year":"2020","journal-title":"Pharmgenomics Pers Med"},{"key":"R40-20261002","first-page":"257","article-title":"Drug metabolizing enzymes and summary of technical guidelines for drug target gene detection.","volume":"3","year":"2015","journal-title":"Practical Organ Transfer Journal of Plant Electronics"},{"key":"R41-20261002","doi-asserted-by":"crossref","first-page":"1463595","DOI":"10.3389\/fphar.2024.1463595","article-title":"Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study.","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R42-20261002","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/jcpt.13804","article-title":"Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.","volume":"47","author":"Ebid","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R43-20261002","doi-asserted-by":"crossref","first-page":"e73520","DOI":"10.2196\/73520","article-title":"Effectiveness of eHealth for medication adherence in renal transplant recipients: Systematic review and meta-analysis.","volume":"27","author":"Zhou","year":"2025","journal-title":"J Med Internet Res"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:14Z","timestamp":1790913614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000604","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}